Ultrasonic Evaluation of Carbon Dioxide Laser Effects on Patients With Genitourinary Syndrome
1 other identifier
observational
31
1 country
1
Brief Summary
The aim of the study was to evaluate the efficacy of vaginal Carbon Dioxide Laser treatment in patients with Genitourinary Syndrome of Menopause on the improvement of Vulvovaginal Atrophy (VVA) and stress urinary incontinence (SUI) by objective parameters and in particular to assess the ultrasound measurement of specific vaginal parameters in order to evaluate a new objective tool of assessment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 11, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 9, 2022
CompletedFirst Submitted
Initial submission to the registry
July 18, 2023
CompletedFirst Posted
Study publicly available on registry
November 21, 2023
CompletedNovember 21, 2023
November 1, 2023
11 months
July 18, 2023
November 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluating the effectiveness of Carbon Dioxide Laser in patients with genitourinary syndrome of menopause in terms of the improvement in a specific vaginal ultrasonographic parameters
To evaluate the primary outcome, we examined the following vaginal ultrasonographic parameters (by transvaginal probe), both before and after 3 vaginal Carbon Dioxide Laser applications: * Thickness of the anterior vaginal walls (VWT) at the level of the introitus of the inferior vaginal third (expressed in millimeters); * Thickness of the posterior VWT at the level of the introitus of the inferior vaginal third (expressed in millimeters). Positive outcomes are evidenced if thickness (expressed in millimeters) is increased after treatment in both anterior and posterior vaginal walls.
4 months
Eligibility Criteria
Menopausal patients that attended our clinic of menopausal disorders and performed Carbon Dioxide Laser therapy for genitourinary syndrome. In order to enroll patients with Genitourinary Syndrome of Menopause, the investigator used the Vaginal Health Index (VHI), Vulvar Health Index (VuHI), and Stress Urinary Incontinence (SUI) scales. * The VHI score assesses vaginal health, with a cutoff of \<15 on the index to diagnose patients with atrophy \[ranging from "complete atrophy" (0) to "optimal vaginal health" (25)\]. * The VuHI score assesses vulvar health, on a scale from normal (0) to severe (3). The overall score ranges from 0 to 24, and its cutoff for diagnosing atrophic vulva is \>8 on the index. * Stress Urinary Incontinence (SUI) is characterized by sudden urine loss. Evaluated using the Stamey score, with ratings of no incontinence (0) to severe incontinence (3).
You may qualify if:
- Age \<75 years, menopause (naturally, pharmacologically or surgically induced, at least 12 months)
- Negative Papanicolaou test (PAP) performed within 12 months before enrolment. and one of the following:
- Presence of vulvovaginal atrophy \[vaginal health index (VHI) \< 15\]
- Initial Urinary Incontinence based on patient history = 1 (according to the "Stamey incontinence score of Stress Urinary Incontinence" - min. 0 = no incontinence, max. 3 = severe incontinence)
- Standardized stress provocation test
You may not qualify if:
- Age \>45 years
- The presence of vaginal lesions (active or in the previous 30 days).
- genitourinary tract infection.
- abnormal uterine bleeding.
- use of hormone replacement therapy up to 6 months before enrolment.
- history of photosensitivity disorder or use of photosensitizing drugs.
- genitals prolapse (grade II - III according to the Pelvic Organ Prolapse Quantification)
- a serious or chronic condition that could interfere with study compliance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
FPG gemelli RCCS
Rome, Lazio, 00168, Italy
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 18, 2023
First Posted
November 21, 2023
Study Start
January 11, 2021
Primary Completion
December 12, 2021
Study Completion
January 9, 2022
Last Updated
November 21, 2023
Record last verified: 2023-11